TCT 2023 | SWEDEHEART, Evolution at 5 Years

This register included 42,887 patients receiving FFR or iFR to assess moderate lesions, and 80% of them underwent FFR.

TCT 2023 | SWEDEHEART, evolución  a 5 años

Population characteristics were similar, except that the iFR group had more women, with more diabetes, MI, stroke and chronic obstructive pulmonary disease (COPD).

Primary end point was a composite of all cause death, MI and unplanned revascularization.

At 5 years, there were no significant differences in primary end point, or individual events, which include all cause death, MI and unplanned revascularization. Also, MACE were analyzed in treated and deferred patients, with no differences neither in MACE nor in individual events. 

At group sub-analyzis, no differences were found either, between FFR and iFR patients. 

Read also: TCT 2023 | EVOLUT Low Risk: 4-Year Follow-up.

In conclusion, the authors determined that, at 5 years, there were no significant differences in MACE or in the events of all cause death, MI and unplanned revascularization. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the editorial board of SOLACI.org.

Presented by Matthias Götberg during TCT 2023.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...